acta diurna · run record
2026-09-18-medtech
18 September 2026 ·partial
| # | stage | model | verdict | retries | notes | cost |
|---|---|---|---|---|---|---|
| 01 | nuncio | deepseek/deepseek-v4-flash | — | — | rss:FierceBiotech failed (Cannot convert object to primitive value) [optional] | rss:Fierce Pharma failed (Cannot convert object to primitive value) [optional] | $0.0006 |
| 02 | bulletins | anthropic/claude-sonnet-5 | — | — | "FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A": spiked (2 redispatch) | "A geriatrician explains why AI for older adults deserves careful scrutiny": pass (0 redispatch) | "Zocdoc for chatbots and what’s new with Medicare’s ACCESS": pass (1 redispatch) | $0.0850 |
| 03 | dispatch | anthropic/claude-sonnet-5 | pass | — | $0.0567 | |
| 04 | rounds | anthropic/claude-sonnet-5 | pass | — | $0.0340 | |
| 05 | illuminate-rounds | — | — | — | skipped: no FAL_KEY — "The Elder at the Foot of the Bed" publishes without a plate | $0.0000 |
| 06 | spikes | — | — | — | SPIKED "FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A": The sole cited FDA URL does not resolve, so the artifact's attributions to "the FDA's press announcement" cannot be verified against the underlying announcement.; The pathology details, including "progressive damage across multiple organ systems," "developmental regression," and "loss of speech and mobility," are not supported by the supplied source summary.; The mechanism claim that Fayuvi is "administered as a one-time gene therapy intended to supply a working copy of the deficient enzyme's gene" is not supported by the supplied source summary.; The unsupported in-universe meta-commentary beginning "The Specola notes that this bulletin reflects only what is confirmed" should be removed; it also claims an independent-verification status not established in the source material.; The closing claim that MPS IIIA was "previously without any approved intervention" overstates the supported wording. The supplied source supports "first treatment" and "no prior FDA-approved treatment," not the broader absence of any approved intervention. | — |
| the day's wage | $0.1763 | |||||